Auris Medical Holding (EARS) Announces Completion of Keyzilen Phase 3 TACTT3 Enrollment
Tweet Send to a Friend
Auris Medical Holding AG (Nasdaq: EARS) announced that it has completed patient enrollment in the Phase 3 TACTT3 clinical trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
